Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yohannes T Ghebremariam

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Diabetes Research|January 16, 2016
Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin SensitizersLi Lai, Yohannes T Ghebremariam
Trends in Cardiovascular Medicine|February 24, 2009
Endothelial nicotinic acetylcholine receptors and angiogenesisJohn P Cooke, Yohannes T Ghebremariam
The Journal of Clinical Investigation|March 26, 2011
Dietary nitrate, nitric oxide, and restenosisJohn P Cooke, Yohannes T Ghebremariam
Methodist Debakey Cardiovascular Journal|December 4, 2015
Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for TherapyRoman A Sukhovershin, Gautham Yepuri, Yohannes T Ghebremariam
The Journal of Pharmacology and Experimental Therapeutics|October 19, 2013
A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxideYohannes T Ghebremariam, Daniel A Erlanson, John P Cooke
Annals of the New York Academy of Sciences|January 3, 2006
Curcumin inhibits the classical and the alternate pathways of complement activationAmod P Kulkarni, Yohannes T Ghebremariam, Girish J Kotwal
Annals of the New York Academy of Sciences|January 3, 2006
Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alternative complement pathwaysYohannes T Ghebremariam, Odutayo O Odunuga, Kristen Janse, et al.
Journal of Biomolecular Screening|March 31, 2012
Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screeningYohannes T Ghebremariam, Daniel A Erlanson, Keisuke Yamada, et al.
Annals of the New York Academy of Sciences|January 3, 2006
Intervention strategies and agents mediating the prevention of xenorejectionYohannes T Ghebremariam, Scott A Smith, J B Anderson, et al.
The Journal of Surgical Research|August 21, 2009
Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in ratsYohannes T Ghebremariam, Gert Engelbrecht, Marilyn Tyler, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Diabetes Research|January 16, 2016
Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin SensitizersLi Lai, Yohannes T Ghebremariam
Trends in Cardiovascular Medicine|February 24, 2009
Endothelial nicotinic acetylcholine receptors and angiogenesisJohn P Cooke, Yohannes T Ghebremariam
The Journal of Clinical Investigation|March 26, 2011
Dietary nitrate, nitric oxide, and restenosisJohn P Cooke, Yohannes T Ghebremariam
Methodist Debakey Cardiovascular Journal|December 4, 2015
Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for TherapyRoman A Sukhovershin, Gautham Yepuri, Yohannes T Ghebremariam
The Journal of Pharmacology and Experimental Therapeutics|October 19, 2013
A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxideYohannes T Ghebremariam, Daniel A Erlanson, John P Cooke
Annals of the New York Academy of Sciences|January 3, 2006
Curcumin inhibits the classical and the alternate pathways of complement activationAmod P Kulkarni, Yohannes T Ghebremariam, Girish J Kotwal
Annals of the New York Academy of Sciences|January 3, 2006
Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alternative complement pathwaysYohannes T Ghebremariam, Odutayo O Odunuga, Kristen Janse, et al.
Journal of Biomolecular Screening|March 31, 2012
Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screeningYohannes T Ghebremariam, Daniel A Erlanson, Keisuke Yamada, et al.
Annals of the New York Academy of Sciences|January 3, 2006
Intervention strategies and agents mediating the prevention of xenorejectionYohannes T Ghebremariam, Scott A Smith, J B Anderson, et al.
The Journal of Surgical Research|August 21, 2009
Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in ratsYohannes T Ghebremariam, Gert Engelbrecht, Marilyn Tyler, et al.
Pageof 3